Dermpath Diagnostics
Dermpath Diagnostics, a wholly-owned subsidiary of Quest Diagnostics, is a US specialty dermatopathology laboratory brand operating 14 labs staffed by 75+ board-certified dermatopathologists, serving dermatologists, podiatrists, and patients with skin pathology diagnostics, advanced genomic testing, and MRD services.
- Company typePrivate
- Founded1981
- HeadquartersSecaucus, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Dermpath Diagnostics does
Dermpath Diagnostics is a US-based specialty dermatopathology laboratory brand operating as a wholly-owned subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), the diagnostic information services company headquartered in Secaucus, New Jersey. Quest acquired Dermpath in 2013, consolidating predecessor labs (Troy & Associates, founded 1981 in Brookfield, WI; Central Florida, founded 1985) into a unified dermatopathology network. The company provides microscopic examination of skin tissue, hair, and nails by a network of over 75 board-certified dermatopathologists, serving dermatologists and podiatrists across the United States through 14 laboratory locations in 10 states with nationwide specimen acceptance and a 24–48 hour turnaround time.
The company's technology stack centers on dermatopathology diagnostics with an expanding advanced genomic testing portfolio. Core offerings include histopathologic evaluation, special stains, immunoperoxidase stains, and direct/indirect immunofluorescence (housed in the dedicated Institute for Immunofluorescence). High-value genomic tests for melanoma include MelaNodal Predict (nodal staging prediction), MelanomaSEQ and MelanomaSEQPlus (comprehensive genomic profiling), and BRAF testing. Haystack MRD, developed through a technology partnership with Haystack Oncology, extends the portfolio into circulating tumor DNA (ctDNA) minimal residual disease testing for cancer patients. Quanum Lab Services Manager provides workflow management with integration across 600+ EMR systems, and the proprietary ASSIST system tracks specimens from receipt through result delivery.
Dermpath operates a B2B professional services revenue model billed primarily through health insurance reimbursement. It is in-network with Aetna, Horizon Blue Cross Blue Shield, UnitedHealthcare, traditional Medicare, and Medicaid, with self-pay pricing and financial assistance for uninsured patients. The customer base spans dermatology practices (primary), podiatric physicians (through the Institute for Podiatric Pathology), health plans, and patients. Go-to-market is direct enterprise field sales to dermatology and podiatry practices, supported by educational channels (Dermpath University, Dermpath Bowl at AAD annual meetings), MIPS/Quality Payment Program consulting, and the patient-facing Spot the Spot skin cancer awareness program.
Dermpath Diagnostics firmographics
Firmographics- Name
- Dermpath Diagnostics
- Legal name
- Dermpath Diagnostics (operating as brand of Quest Diagnostics)
- Website
- https://dermpathdiagnostics.com
- Company type
- Private
- Founded year
- 1981
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Dermpath Diagnostics, a wholly-owned subsidiary of Quest Diagnostics, is a US specialty dermatopathology laboratory brand operating 14 labs staffed by 75+ board-certified dermatopathologists, serving dermatologists, podiatrists, and patients with skin pathology diagnostics, advanced genomic testing, and MRD services.
- Ownership category
- akta.pro rank
Dermpath Diagnostics industry classification
Industry- Product category
- Dermatopathology Diagnostic Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Dermatopathology (HLAKACAC)
- akta.pro secondary industries
- Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA), Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)
Keywords
Where Dermpath Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Secaucus
- HQ country
- United States
- HQ region
- North America
Offices14 records
Markets served
Dermpath Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Laboratory Diagnostic Services: Professional laboratory services for dermatopathology diagnosis billed to health insurance providers. Services include histopathologic evaluation, special stains, immunoperoxidase stains, immunofluorescence, and advanced genomic testing. Revenue generated through insurance claims submission.
- Direct Patient Billing: Self-pay pricing for uninsured patients and those not using insurance coverage. Good Faith Estimates available upon request. Financial assistance programs offered.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance-based laboratory services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Dermpath Diagnostics product offering
Product offeringCore offering
Dermpath Diagnostics provides dermatopathology diagnostic laboratory services, including microscopic examination of skin tissue, hair, and nails by 75+ board-certified dermatopathologists, supported by special stains, immunoperoxidase staining, direct/indirect immunofluorescence, and advanced genomic profiling tests for melanoma (MelaNodal Predict, MelanomaSEQ, MelanomaSEQPlus, BRAF testing). The company also offers Haystack MRD ctDNA-based minimal residual disease testing for cancer patients, podiatric pathology through the Institute for Podiatric Pathology, and the Quanum physician portal integrating with 600+ EMR systems.
Product overview
Dermpath Diagnostics operates as a dermatopathology diagnostic services company offering a unified portfolio of specialized laboratory testing and professional services. The core offering is dermatopathology services with microscopic examination of skin tissue by board-certified dermatopathologists, supplemented by advanced genomic testing including MelaNodal Predict™, MelanomaSEQ®, and MelanomaSEQPlus® for melanoma patients. The company provides Haystack MRD™ for minimal residual disease testing in cancer patients. Supporting services include clinical testing (ANA Cascade, QuantiFERON®, T-SPOT®.*TB*, Prebiologics Panel), specialized divisions (Institute for Immunofluorescence, Institute for Podiatric Pathology), and educational platforms (Dermpath University®, Spot the Spot™). Integration with over 600 EMR systems and Quanum® Lab Services Manager workflow software enables streamlined operations for клиницистов.
Differentiator
Problem solved
Functional benefit
Brands
- Haystack MRD: Purpose-built, high-precision MRD (Minimal Residual Disease) testing for cancer patients, providing ultrasensitive circulating tumor DNA (ctDNA) testing.
- Dermpath University
- Dermpath Bowl
- Spot the Spot
Products and services
- Dermatopathology Diagnostic Services Core diagnostic service providing microscopic examination of skin tissue, hair, and nails by 75+ board-certified dermatopathologists for definitive diagnosis of skin disorders including melanoma, skin cancers, immunologic, infectious, and pediatric conditions. Serves referring dermatologists, dermatology practices, and podiatrists.
- Haystack MRD
- MelaNodal Predict
- MelanomaSEQ
- MelanomaSEQPlus
- BRAF Testing
- Direct and Indirect Immunofluorescence
- Institute for Podiatric Pathology Services
- Quanum Lab Services Manager
- TC/PC (Technical/Professional Component) Solution with MIPS Consulting
- HPV Typing
- Mycology and Bacteriology Analysis
- B Cell and T Cell Gene Rearrangement Studies
- Prebiologics Panel
Quantifiable outcome
- 24-48 hour turnaround time for dermatopathology results
- +1 more outcomes
Companies that use Dermpath Diagnostics
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Dermpath Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature7 records
Dermpath Diagnostics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and supporting.
- Quest DiagnosticscoreQuest Diagnostics is the parent company of Dermpath Diagnostics. Dermpath Diagnostics operates as a subsidiary brand under Quest Diagnostics, utilizing shared resources including the Quest Diagnostics comprehensive oncology testing portfolio, EMR integration platform (Quanum), and billing infrastructure through MyDocBill.com.
- Haystack OncologycoreTechnology partnership for Haystack MRD ctDNA testing based on more than 20 years of research developed by cancer genomics pioneers. Haystack MRD's purpose-built, high-precision science delivers novel insights for optimal treatment decision-making.
- Quest Diagnostics Nichols InstitutesupportingPartnership with Quest Diagnostics Nichols Institute for clinical and advanced testing menu including all-encompassing clinical testing, dermatologic disease state monitoring, and specialized testing.
- AetnacorePreferred laboratory status with Aetna health insurance. Dermpath Diagnostics is in-network provider for Aetna members.
- Horizon Blue Cross Blue ShieldcorePreferred laboratory status with Horizon health insurance. Dermpath Diagnostics is in-network provider for Horizon members.
- UnitedHealthcarecorePreferred laboratory status with UnitedHealthcare. Dermpath Diagnostics is in-network provider for UnitedHealthcare members.
- Healthcare Quality Consulting (Quest HPQI)supportingPartnership for MIPS consulting services helping practices navigate Quality Payment Program requirements. Quest Healthcare Performance and Quality Improvement Consulting Services provides MIPS assistance to Dermpath Diagnostics customers.
- EMR System VendorssupportingIntegration partnerships with 600+ EMR systems through Quanum Lab Services Manager for seamless electronic medical record connectivity.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Dermpath Diagnostics competitors and assessment
Company assessmentDirect peers
- Inform Diagnostics (now PathAI): Specialty anatomic pathology and dermatopathology provider now part of PathAI, offering both routine and AI-augmented pathology reads. Competes directly with Dermpath in dermatopathology and is actively pushing AI-driven disruption of the same workflow.
- Cockerell Dermatopathology: Independent dermatopathology specialty laboratory serving dermatologists across the US. Direct competitor in the same dermatopathology diagnostic niche with a comparable specialist-physician customer base and similar test menu.
- Caris Life Sciences: Oncology-focused molecular profiling and pathology lab offering comprehensive genomic profiling for solid tumors including melanoma. Overlaps with Dermpath's MelaNodal Predict, MelanomaSEQ, and BRAF testing menu in the melanoma and advanced oncology segments.
- Dermatopathology Laboratory of Central States: Independent dermatopathology reference lab serving dermatologists and podiatrists in the US. Directly comparable in scope, customer base, and service offering to Dermpath Diagnostics.
- Pathology Watch (by Sonic Healthcare): Dermatopathology and digital pathology lab serving dermatology groups nationwide, providing reads, digital slides, and integrated workflow. Directly competes with Dermpath for dermatology specimen volume and offers similar EMR-integrated services.
Emerging players
- Guardant Health: Liquid biopsy and MRD testing company with Guardant Reveal for MRD detection. Competitor in the same MRD space that Dermpath's Haystack MRD targets, particularly in oncology treatment decision-making.
- Natera: Specialized in ctDNA-based minimal residual disease (MRD) testing, including Signatera for solid tumor MRD. Directly comparable to Dermpath's Haystack MRD offering in the oncology MRD market that Dermpath/Quest is entering.
Broad incumbents
- ARUP Laboratories: National reference laboratory within the University of Utah system offering broad anatomic pathology, dermatopathology, and advanced molecular testing. Overlaps with Dermpath's test menu as a larger academic-affiliated reference competitor.
- BioReference Health (formerly BioReference Laboratories / OPKO Health subsidiary): National full-service clinical and anatomic pathology lab including dermatopathology. Competes for the same referring physician and dermatology group specimen volume across a broader test menu.
- Foundation Medicine: Comprehensive genomic profiling company (Roche subsidiary) for solid tumors including melanoma. Overlaps with Dermpath's MelanomaSEQ and BRAF testing in advanced oncology decision support.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Dermpath Diagnostics social profiles
Digital presenceDermpath Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dermpath Diagnostics leadership team
Management profileNumber of profiles
Profiles1 record
Dermpath Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries15 records
Dermpath Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dermpath Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dermpath Diagnostics
What does Dermpath Diagnostics do?
Dermpath Diagnostics provides dermatopathology diagnostic laboratory services, including microscopic examination of skin tissue, hair, and nails by 75+ board-certified dermatopathologists, supported by special stains, immunoperoxidase staining, direct/indirect immunofluorescence, and advanced genomic profiling tests for melanoma (MelaNodal Predict, MelanomaSEQ, MelanomaSEQPlus, BRAF testing). The company also offers Haystack MRD ctDNA-based minimal residual disease testing for cancer patients, podiatric pathology through the Institute for Podiatric Pathology, and the Quanum physician portal integrating with 600+ EMR systems.
Is Dermpath Diagnostics a public or private company?
Dermpath Diagnostics is a private company. It is classified as corporate owned and is currently operating.
When was Dermpath Diagnostics founded?
Dermpath Diagnostics was founded in 1981. It employs 5,001 to 10,000 people.
Where is Dermpath Diagnostics based?
Dermpath Diagnostics is headquartered in Secaucus, United States, in the North America region.
How does Dermpath Diagnostics make money?
Two revenue lines are on record. Laboratory Diagnostic Services are the primary driver. The others are direct Patient Billing.
Who are Dermpath Diagnostics's main competitors?
Direct peers on record are Inform Diagnostics (now PathAI), Cockerell Dermatopathology, Caris Life Sciences, Dermatopathology Laboratory of Central States and Pathology Watch (by Sonic Healthcare). Emerging players are Guardant Health and Natera. Broad incumbents are ARUP Laboratories, BioReference Health (formerly BioReference Laboratories / OPKO Health subsidiary) and Foundation Medicine.
Does Dermpath Diagnostics have an API?
No public API is recorded for Dermpath Diagnostics.
What industry is Dermpath Diagnostics in?
Dermpath Diagnostics's product category is Dermatopathology Diagnostic Services. Its primary akta.pro industry code is HLAKACAC, Dermatopathology, with a secondary code of HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology). Its NAICS code is 621511 and its SIC code is 8071.